The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
1202001 Informal Interpretation
Agency Information Collection Activities; Proposed Collection; Comment Request; Extension (Regs BEMZ PRA)
20120462: Twin Eagle Resource Management, LLC; Black Hills Corporation
20120446: Macquarie Partners II Intl.; WCA Waste Corporation
20120432: Carl C. Icahn; CVR Energy, Inc.
20120490: Lightyear Fund II, L.P.; Genworth Financial, Inc.
20120482: H. Lawrence Culp, Jr.; Danaher Corporation
20120479: Essex Woodlands Health Ventures VIII, L.P.; Smith & Nephew plc
20120474: Forum Energy Technologies, Inc.; The Jack Coleman Trust and Janet Coleman Trust
20120460: TransDigm Group Incorporated; AmSafe Global Holdings, Inc.
20120439: Lam Research Corporation; Novellus Systems, Inc.
20120455: Jay L. Sedwick; AccuSpec Main Street, LLC
20120453: GT Investors, Inc.; ARC Energy Fund 5 United States LP
20120452: Lime Rock Partners V, L.P.; Archer Limited
20120427: Fossil, Inc.; Henrik Jorst
20120456: Audax Private Equity Fund III, L.P.; Morgenthaler Management Partners VII, L.P.
20120440: Post Oak Companies, LP; Prospect Capital Corporation
20120431: Alexion Pharmaceuticals, Inc.; Enobia Pharma Corp.
Laboratory Corporation of America Holdings, and Orchid Cellmark Inc.
The Commission required laboratory testing companies Laboratory Corporation of America Holdings and Orchid Cellmark Inc. to divest a portion of Orchid's paternity testing business, to resolve the FTC complaint alleging that LabCorp's $85.4 million acquisition of Orchid would have an anticompetitive impact in the market for paternity testing services used by government agencies. Under the proposed settlement order, the portion of Orchid's U.S. paternity testing business that is focused on sales to government agencies, and related assets, will be sold to another testing company, DNA Diagnostics Center (DDC). On 2/1/2012, the FTC approved a final order.